3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Sarcoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Inhibition, Psychological
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Hepatoblastoma
1
Glioma
1
Ependymoma
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
7
Nivolumab
6
enfortumab vedotin
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
4
sacituzumab govitecan
3
Docetaxel
3
CTLA-4 Antigen
3
cabozantinib
2
Taxes
2
Paclitaxel
2
Gemcitabine
2
temsirolimus
1
relatlimab
1
lenvatinib
1
eribulin
1
avelumab
1
atezolizumab
1
Valproic Acid
1
Sirolimus
1
Single Person
1
Radiosurgery
1
Platinum
1
Immunoglobulin G
1
Disulfides
1
Cisplatin
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
tazemetostat
×
30 days
×
Clear all
No trials found.